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Abstract
Background: In cardiac surgery, cardiopulmonary bypass (CPB) and unfractionated heparin have negative effects on blood
platelet function. In acute normovolemic haemodilution autologous unfractionated heparinised blood is stored ex-vivo and
retransfused at the end of the procedure to reduce (allogeneic) transfusion requirements. In this observational study we
assessed whether platelet function is better preserved in ex vivo stored autologous blood compared to platelet function in
the patient during CPB.
Methodology/Principal Finding: We measured platelet aggregation responses pre-CPB, 5 min after the start of CPB, at the
end of CPB, and after unfractionated heparin reversal, using multiple electrode aggregometry (MultiplateH) with adenosine
diphosphate (ADP), thrombin receptor activating peptide (TRAP) and ristocetin activated test cells. We compared blood
samples taken from the patient with samples taken from 100 ml ex-vivo stored blood, which we took to mimick blood
storage during normovolemic haemodilution. Platelet function declined both in ex-vivo stored blood as well as in blood
taken from the patient. At the end of CPB there were no differences in platelet aggregation responses between samples
from the ex vivo stored blood and the patient.
Conclusion/Significance: Ex vivo preservation of autologous blood in unfractionated heparin does not seem to be
profitable to preserve platelet function.
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Introduction
Cardiac surgery is associated with blood platelet dysfunction
and perioperative coagulation disturbances [1,2]. The use of
cardiopulmonary bypass (CPB) (resulting in haemodilution,
hemostasis activation by contact with foreign surfaces and tissue
factor liberation), blood suction, and the concomitant upregulation
of inflammatory pathways all contribute to the activation and
mechanical destruction of platelets [3,4]. Moreover, vasodilata-
tion, and blood loss contribute to a coagulopathic status at the end
of surgery. Unfractionated heparin is universally used to
anticoagulate patients during CPB, but also to prevent or treat
other systemic thrombotic complications. Unfractionated heparin
has long been known to possess platelet activating properties, but
only recently it has been demonstrated that unfractionated heparin
promotes platelet responsiveness via its ability to initiate aIIbb3-
mediated outside-in signaling [5]. During cardiac surgery several
techniques are advocated to preserve coagulation factors and
platelet function, in order to reduce allogeneic transfusion. These
techniques include intra-operative platelet anesthesia [6,7],
platelet-rich plasma harvesting [8] and acute normovolemic
haemodilution (ANH) with sequestration of unfractionated
heparinised autologous blood [9,10]. Intraoperative autologous
blood can be donated prior heparinisation, after heparinisation
but before bypass, and after stabilisation during bypass. In this
study, we sequestrated a small volume of autologous blood after
heparinisation but prior CPB as is our common practice, to
mimick blood storage in the context of normovolemic haemodi-
lution. We hypothesized that platelets function would be better
preserved in ex vivo sequestrated unfractionated heparinised
autologous blood compared to platelet function in the patient, as
platelets in the patient are exposed to other activating mechanisms
including the CPB circuit. We measured platelet aggregation
responses in cardiac surgical patients and in sequestrated
unfractionated heparinised autologous blood during the period
of CPB with multiple electrode impedance aggregometry (Multi-
plateH, Dynabyte, Munchen Germany).
Methods
Patients
Twenty-six patients who underwent routine coronary artery
bypass grafting (CABG) or valve surgery were included for this
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review board of the University Medical Center Groningen and
written informed consent. Patients on aspirin were included,
clopidogrel was stopped at least 5 days prior to operation.
Excluded were patients who were on unfractionated heparin or
intravenous tirofiban prior to surgery, patients with a pre-
operative platelet count of ,150610
9/L or an INR.2.0.
Anaesthesia was standardised using bispectral index guided total
intravenous anaesthesia with propofol, supplemented by sufentanil
(3–4 mg/kg). All patients received tranexamic acid (30 mg/kg).
Before CPB, 300 U/kg unfractionated bovine heparin was
administered, supplemented if necessary to maintain an activated
clotting time of at least 400 sec (ACT, HemochronH, Technidyne,
NY, USA). At the end of CPB, unfractionated heparin was
reversed with protamine chloride in a 1:1 ratio. The open CPB
circuit included the use of a membrane oxygenator, roller pumps,
uncoated tubings, hyperkalemic cardioplegia (St Thomas solution
2, PlegisolH, Hospira, Lake Forest, Ill, US) and was primed with
1.5 L lactated Ringer’s solution and 500 mL 10% Hydroxyethyl
starch (Haes 10%, FreseniusH, Bad Homburg Germany). No cell
saver was used. The haemostatic profile was measured with a
viscoelastic measurement (RoTEM thromboelastometry, Penta-
pharmH, Munich, Germany). Whole blood coagulation was
initiated with tissue factor (ExTEM) without citration and
recalcification. Fibrinogen (Clauss) and RoTEM measurements
were taken after induction of anaesthesia and after unfractionated
heparin reversal.
Blood samples from the patients were drawn gently from an
unheparinised 20G arterial line, after discarding 4 times the
volume of the connection line. Samples were taken after induction
of anaesthesia (pre CPB), 5 min after the start of CPB, at the end
of CPB, and after unfractionated heparin reversal.
Preparation of autologous blood. After adequate
unfractionated heparinisation as assessed with ACT time
.400 sec, just before the start of CPB, a sterile blood
conservation bag without additives was filled with 100 ml of
autologous blood. This procedure was to mimick blood storage
during normovolemic haemodilution, but in actual normovolemic
haemodilution much larger volumes of blood are stored. This bag
was placed on a stirring device (IKA Laboratory Equipment MK
2) and set at 100 cycles/min at room temperature to prevent stasis
and spontaneous agglutination of platelets.
Blood samples from the autologous blood bag were taken 5 min
after the start of CPB and at the end of CPB. All blood samples
taken for platelet function measurements were stored in plastic
tubes with hirudin as recommended by the manufacturer (Multi-
plateH, Dynabyte Medical, Munchen, Germany).
Platelet Aggregometry. The Multiplate (DynabyteH
Medical, Munchen, Germany) is a multiple 5 channel whole
blood impedance electrode aggregometer with disposable testcells
(MEA). The platelet aggregation response was studied with
adenosine diphosphate (6.4 mM, ADP), high dose ristocetin
(50 uL, 0,77 mg/ml) and thrombin receptor activating peptide
(TRAP, 32 mM) a strong activator to assess maximal activation
response. ADP and TRAP are direct platelet activators, ristocetin
is an indirect activatior which induces von Willebrand factor-
mediated platelet activation. The ASPI test with arachidonic acid
(0,5 mM), a sensitive platelet aggregation response activator was
used to assess aspirin effects on platelet function [11].
Statistical Analysis. A decrease in platelet receptor response
of 25–50% during CPB has been reported [12–14]. A difference of
25% between the platelet aggregation response in the autologous
blood bag and in the patient was considered clinically relevant and
therefore used for sample size calculation (n=23, power=0.8,
P,0.05), based on data from the study of Toth [15]. Our data had
a normal distribution. Student’s t-test for independent samples,
was used to assess differences between bag and patient. Repeated
Measures Analysis of Variance for multiple comparisons were used
to assess a trend over time within the patient. A P-value,0.05 was
considered significant. Data were not corrected for haemodilution.
Results
Blood samples were obtained from 26 patients, 16 patients took
aspirin. The demographic data and intraoperative changes in
haemostatic profile are shown in table 1. The ADP and TRAP
induced intraoperative aggregation response decreased progres-
sively (p
ADP=0.002, p
TRAP,0.001, for trend over time, table 2).
Already in the sample taken 5 minutes after the start of CPB, a
significant decline in both ADP- and TRAP-induced platelet
aggregation was observed in comparison to aggregation measured
in the sample taken after induction of anesthesia (p
ADP=0.004,
p
TRAP=0.001). Ristocetin-induced platelet aggregation also
declined over time, but the difference in aggregation response
between the pre-CPB and 5 minutes after CPB sample was not
statistically significant. In samples taken after CPB, ADP- and
ristocetin-induced aggregation were lower compared to pre-CPB
levels (p
ADP,0.01, p
RISTO=0.04). In contrast, TRAP-induced
aggregation appeared to increase post-CPB, and the post-CPB
values were not significantly different from the pre-CPB values
(p
TRAP=0.14, table 2).
Our study population had reduced platelet aggregation
responses in the ASPI test (table 1), which may reflect an existing
partial platelet dysfunction in these patients [16]. Nevertheless,
preoperative viscoelastic coagulation measurements performed by
thromboelastrometry were within normal ranges in all patients.
The measurements of the ADP-, TRAP-, and ristocetin-induced
platelet aggregation in the first sample taken from the ex vivo
stored autologous blood were not different from the samples taken
prior to CPB from the patients (table 2). At the end of the CPB
period, the ADP induced platelet aggregation in the ex-vivo stored
blood was decreased compared to the first sample taken from the
blood bag (p
ADP=0.02, table 2). Decreases in TRAP- and (to a
lesser extend) ristocetin-induced platelet aggregation were also
observed, but these differences were not statistically significant
(p
TRAP=0.08, p
RISTO=0.52). At the end of CPB there was no
difference in the platelet aggregation response with all activators
between the samples from the ex-vivo stored autologous blood and
samples taken from the patient (table 2).
Discussion
In this observational study we found no difference in the platelet
aggregation induced by ADP, TRAP, or ristocetin between
samples taken from cardiac surgical patients at the end of CPB
and ex-vivo stored heparinised autologous blood. In addition, we
found a progressive decrease of ADP- and TRAP-induced platelet
aggregation response during CPB, which was already apparent at
5 minutes after the start of CPB. This rapid decrease in platelet
aggregation response likely reflects the initiation of CPB, as these
findings were not obtained in the sequestrated heparinized blood
bag.
Several explanations have been offered for the decrease in
platelet function during CPB [3,4]. The decrease in platelet
function in relation to CPB has been demonstrated in many
studies in cardiac surgical patients [1,13,14,17–20]. These studies
are difficult to compare as several methods have been used for the
measurement of platelet function, several preservatives were used
for storage and sampling and either whole blood or platelet rich
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study platelet aggregation during CPB and also found a significant
decrease in TRAP- and ADP-induced platelet aggregation, but in
this study platelet aggregation was assessed in samples taken
30 min after initiation of CPB. Laga [20] suggested that
haemodilution is a major confounder in the measured changes
in platelet function during CPB. Recently, an in vitro study in
healthy volunteers demonstrated that platelet counts below the
normal range due to haemodilution may affect the Multiplate
measurements, although even severely diluted samples may give
results within the normal range [22]. In our study population, we
observed a decrease in platelet count during CPB with a mean
platelet count below the normal range. Therefore an effect of
haemodilution cannot be excluded. Nevertheless, the decline in
platelet function in the patient with decreasing platelet count was
not different from the platelet function decline in the ex-vivo
stored blood, in which the platelet count was preserved. In our
study we did not perform actual isovolemic haemodilution with a
clinically relevant volume substitution. Further haemodilution may
have obscured the differences caused by unfractionated heparin-
isation and the artificial surfaces of the storage bag and the
cardiopulmonary bypass equipment. Our study was simply
designed to mimick the effects of blood storage in the context of
normovolemic haemodilution. Another limitation of our study is
that the results only pertain to practices where blood is donated
prior to haemodilution and bypass. If bypass is started first, blood
in the storage bag will be haemodiluted and exposed to the initial
damaging effects of CPB. Our study suggests that these effects may
not be neglectible. Flom-Halvorsen et al. also assessed the quality
of intraoperative autologous blood donation preserved in unfrac-
tionated heparin. They found a small increase in beta-thrombo-
globulin after storage and suggested that heparinised autologous
blood was an ideal blood product to restore hemostatic effects
[23]. They however did not compare platelet function of the stored
blood with platelet function in samples taken from the patients. As
we did not measure beta-thromboglobulin we cannot relate our
results to their findings. The other preservative widely used for
intraoperative autologous blood storage is a citrate containing
solution. Citrate, however, functions as an anticoagulant by
Table 2. Platelet activation in patients on CPB and in ex vivo
stored unfractionated heparin-anticoagulated blood.
timepoint Patient CI Blood bag CI P
ADP pre-CPB 59628 47–70 55628 44–67 0.86
5 min CPB 42623 33–42
end CPB 41621 32–50 45623 36–55 0.5
post CPB 39628 27–50
TRAP pre-CPB 103626 92–113 97640 81–113 0.53
5 min CPB 80635 66–94
end CPB 84646 66–103 83633 70–97 0.98
post CPB 92641 75–108
Ristocetin pre-CPB 72633 59–86 70638 54–86 0.87
5 min CPB 64640 48–81
end CPB 54640 38–71 64648 44–84 0.43
post CPB 55640 38–71
CPB=cardiopulmonary bypass, ADP, TRAP, Ristocetin=platelet activators, see
text. Values represent area under the curve in arbitrarily units (U) given as mean
6 standard deviation. CI=95% confidence interval. P values relate to the
difference between samples taken from the patient or from the ex-vivo stored
blood at the corresponding time points.
doi:10.1371/journal.pone.0033686.t002
Table 1. Demographic data of the 26 patients studied.
Age (years) 63615
Gender (m/f) 18/8
CABG/valve surgery/combin(n) 14-10-02
Height (cm) 173611
Weight (kg) 84613
CPB period (min) 109646
Unfractionated heparin U/kg 5286242
Protamine (mg/kg) 5.062.4
Chest tube loss 12 hr postoperative (ml) 5786500
pre CPB post CPB
Platelet count (610
9/L) 209647 133635
**
Haemoglobin (mmol/L) 7.96.1.1 4.960.5
**
Fibrinogen g/L 3.361.0 1.960.8
**
ASPI test (75–136) 49.3633.9 26.2626.7
**
ExTEM ct (35–80 s) 74.4614.6 96.0622.7
**
ExTEM cft (35–160 s) 63.4612.6 93.4638.7
**
ExTEM mcf (53–72 mm) 68.766.1 62.067.5
**
ExTEM a (63–83u)7 6 . 9 63.7 70.169.4
**
Values are mean 6 standard deviation. CPB=cardiopulmonary bypass. CABG=only coronary artery bypass graft, valve=only valve, combin=combination of
CABG+valve surgery. ASPI=arachidon acid activated platelet aggregation response, ExTEM=tissue factor initiated whole blood clotting measured with RoTEM
(thromboelastometry), ct=clotting time, cft=clot formation time, mcf=maximum clot formation (mm), angle a=indicative for speed of clot generation.
**intraoperative change (p,0.05).
doi:10.1371/journal.pone.0033686.t001
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2+ ions. As extracellular calcium is pivotal in platelet
activation, this anticoagulant is not advocated for platelet function
studies using the MultiplateH [24].
Although it appeared plausible that ex-vivo storage of whole
blood in unfractionated heparin would better preserve platelet
function as compared to platelet function in the patient, we found
no differences in platelet function decline between the two
situations. Unfractionated heparin affects platelet function by
paradoxical platelet activating properties, which lead to a net
decline in platelet activatability [5,25–26]. This decline in platelet
functionality is likely caused by irreversible platelet activation by
heparin, which may occur in combination with other effects such
as platelet activation by the storage bag (see below). When platelets
are irreversibly activated, i.e., activated in such a way that granule
contents are secreted, they can no longer be activated by a second
stimulus, a phenomenon which is well known in literature [27].
Possibly the effects of unfractionated heparin on platelet function
as measured by MultiplateH are far more important than the
effects of CPB and the surgical procedure on platelet function.
Platelet function decline ex vivo may be a combination of the
unfractionated heparin effect with effects of the surface of the
blood bag (comparable to the surface of CPB tubings) and the
temporary storage at room temperature, which may also
contribute to platelet activation [28].
In conclusion, we have demonstrated that platelet function is
not better preserved in ex-vivo stored autologous blood anticoag-
ulated with unfractionated heparin as compared to platelet
function in the patient itself during the same period of
cardiopulmonary bypass. Sequestration of autologous blood in
unfractionated heparin, as used for acute normovolemic haemo-
dilution in cardiac surgery patients does not seem to be profitable
to preserve platelet function.
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